Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: An appliance includes a casing having a storage space, a door, a first electronic component disposed outside the casing, a second electronic component disposed at the door, a wire, and a wire guide. The door is disposed at a front of the storage space and configured to open and close at least a portion of the storage space. The wire is configured to electrically connect the first electronic component to the second electronic component. The wire guide is disposed between the casing and the wire and configured to block physical contact between a surface of the casing and the wire.

Abstract: A door for a home appliance includes a door body disposed in front of a storage space of the home appliance. An image sensing device is disposed at the door body. The image sensing device includes a sensing housing with an installation space provided therein, and an image sensor in the installation space to acquire images of the storage space. In addition, a sensor protective cover is disposed between the image sensor and the storage space. The image sensing device is installed in the door and, specifically, is protected by the sensor protective cover, so the image sensing device is less affected by an internal environment of the home appliance, and the durability of the image sensing device can be improved.

Abstract: A door for a home appliance includes a door body disposed in front of a storage space of the home appliance. A lighting device may be disposed at the door body. The lighting device includes a lighting housing with an installation space provided therein, a light source emitting light to the storage space, and a cover plate transmitting light from the light source. Since the lighting device is installed in the door, the lighting device is less affected by the internal environment of the home appliance, and the durability of the lighting device may be improved.

Abstract: A door for a home appliance includes a door frame disposed in front of a storage space of the home appliance, and a door panel coupled to the door frame and including a plurality of panels with an image acquisition module disposed therebetween. A deformation prevention part protrudes on either a surface of the image acquisition module or a surface of the door frame facing the surface of the image acquisition module toward the other. The deformation prevention part prevents the image acquisition module from being deformed by heat in the door. The prevention of the deformation of the image acquisition module is enabled to prevent the image acquisition module from being separated from the door or damaged by excessive deformation.

Abstract: A door for a home appliance includes a door frame disposed in front of a storage space of the home appliance, and having a through-hole at a central portion thereof. A door panel including a plurality of panels is coupled to the door frame. In addition, an installation region is provided in the door panel surrounded by the door frame. An image acquisition module is disposed in a partial space of the installation region, and an air circulation path connected to a flow space is formed in a remaining space of the installation region.

Abstract: A home appliance includes a door. The door includes a door body disposed in front of a storage space of the appliance. An image acquisition module is disposed in the door body. The image acquisition module includes an image sensing device configured to acquire an image of the storage space and a lighting device configured to emit light to the storage space.

Abstract: The application relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers thereof, which modulate the activity of EGFR, a pharmaceutical composition comprising said compounds, and methods of treating or preventing a disease in which EGFR plays a role.

Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.

Abstract: Proposed is a cooking appliance having a function capable of manually opening a door even when a closed state of the door is maintained. The cooking appliance includes: a main body having a cooking chamber defined therein; a door mounted rotatably to the main body; and a latch module provided in the main body and controlling the opening and closing of the door, wherein the latch module includes: a latch installed rotatably at an end thereof, an elastic body installed at a side of the latch and forcing the latch to be rotated in one direction by applying an elastic force to the latch; a driving part installed at a side of the elastic body and supplying power to the latch; a cam provided at a side of the driving part; and a lever bracket having an end thereof connected to the latch.

Abstract: The application relates to a compound having Formula I: which modulates the activity of HER2 and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof plays a role.

Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The present disclosure relates to a quinolinone derivative compound selectively binding to cysteine, an amino acid- or peptide-conjugate thereof, and an antibody-drug conjugate comprising same. Since a conjugate with high chemoselectivity and high yield is formed through a radical pathway induced by visible light, the present disclosure can be applied in various ways to bioconjugation.

Abstract: The application relates to a compound having Formula (I): which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: A cooking appliance includes a cavity having a cooking space therein, a top plate covering an upper portion of the cavity to form an upper space between the top plate and the cavity, and a rear cover covering a rear of the cavity to form a rear space between the rear cover and the cavity, where an upper end opening is formed between the cavity and the rear cover and opens the rear space upward behind the upper space, and the top plate connects to the rear cover while covering the upper space and the upper end opening from above.

Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.

Abstract: The present application provides bifunctional compounds of Formula (I): which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.

Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.

Abstract: The application relates to a compound having Formula I which modulates the activity of HER2 and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof plays a role.